Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 11;6:36650. doi: 10.1038/srep36650

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Migration of CL1-5-F4 cells tested by the transwell assay, and presented as percentages of migrated cells. (b) Invasion of CL1-5-F4 cells tested by the Matrigel transwell assay, and presented as percentages of invaded cells. (c) Microscopical images of the cells migrated to the lower side of the membrane. (d) Microscopical images of the cells invaded through the Matrigel to the lower side of the membrane. Treating cancer cells with either FeDC-E NPs or erlotinib significantly inhibited the migration and invasion capabilities of cells. FeDC-E NPs showed more inhibition activities than erlotinib. (Ctrl) non-treated cells, (FeDC) cells treated with dextran-coated iron oxide nanoparticles, (FeDC-E) cells treated with the erlotinib-conjugated dextran-coated nanoparticles. Percentages of the migrated and invaded cells were quantified using ImageJ software, and the P-values were calculated using the t-Test method assuming unequal variances.